Cost and Access Heres what brand-name pricing looks like right now, as of spring 2026
Monotherapy with a GLP-1 or GLP-1/GIP agent eliminates drug-interaction ambiguity and reduces side-effect burden
The optimal dosing, frequency, and duration of use in humans have not been established through rigorous clinical trials
Dysesthesia The TRIUMPH-4 trial data revealed a notable safety signal: dysesthesia (abnormal sensations like tingling, burning, or numbness) was reported in 8.8% of participants on the 9 mg dose and 20.9% on the 12 mg dose of retatrutide
A 2025 study found that olive leaf extract supplementation improved markers of oxidative stress and inflammation in the liver, highlighting its ability to bolster the bodys natural detoxification defenses and support cellular repair (Lockyer et al., 2025)
Can BHRT help with aging and performance